Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Investor Presentation (March 2018)
23 slides from Actinogen Medical's investor presentation, Mar 19, 2018
Slide 1: Alzheimer Treatment Needs a New Approach – Xanamem
Alzheimer Treatment Needs a New Approach – Xanamem™ Investor Open Briefing March 2018
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to mak
Slide 3: Actinogen Medical (ASX:ACW)
Actinogen Medical (ASX:ACW) • Developing Xanamem for the treatment STOCK METRICS* of Alzheimer's disease (AD) and cortisol associated cognitive impairment ASX CODE ACW Market Capitalisation $37.5m • Xanamem, a novel differentiated Enterprise Value $30.5m mechanism of action: prevents the 52-week Sha
Slide 4: Cortisol inhibition improves cognition – Key Factor in 2014 Acquisition
Cortisol inhibition improves cognition – Key Factor in 2014 Acquisition Two 2004 pilot studies concluded that inhibiting cortisol production in the brain with carbenoxolone improves cognitive function in healthy elderly men & type 2 diabetics – this established Edinburgh Uni hypothesis VERBAL FLUENC
Slide 5: Robust Animal Data with new candidate - Key Factor in 2014 Acquisition
Robust Animal Data with new candidate - Key Factor in 2014 Acquisition Symptomatic and disease modifying effects in mouse models – AUD $25 million invested pre acquisition Cognition: treatment 28 days Amyloid Clearance: treatment 28 days P=0.004 P=0.01 Control 43 ± 21 Control 38 ±3 Treatment Treatme
Slide 6: Xanamem
Xanamem 6 Xanamem™ - novel approach to Alzheimer Dementia
Slide 7: Xanamem
Xanamem • A novel, first in class, potent, orally bioavailable, brain-penetrant, 11βHSD1 inhibitor • Differentiated mechanism of action: blocking cortisol production in the brain • Symptomatic and disease modifying effects in vivo • Well-tolerated – dosed >100 patients/subjects: acceptable clinical
Slide 8: Cortisol: a validated biomarker and target for AD
Cortisol: a validated biomarker and target for AD Cortisol and Alzheimer’s • Recent independent studies support the association between cortisol and AD development and progression1-5 • Cognitive impairment in patients with neuroendocrine dysfunction6-9 • Compelling evidence provided by the Australia
Slide 9: Cortisol, cognitive decline and AD: a growing body of literature
Cortisol, cognitive decline and AD: a growing body of literature Recent relevant reviews: PUBMED:"CORTISOL AND COGNITION" 140 • Cortisol: Mediator of association between Alzheimer's disease and diabetes mellitus? Number of publications 120 (Notarianni, 2017, Psychoneuroendocrinology) 100 • Unified t
Slide 10: XanADu – Phase II Trial
XanADu – Phase II Trial 10 Xanamem™ - novel approach to Alzheimer Dementia
Slide 11: XanADu – Xanamem in Alzheimer's disease
XanADu – Xanamem in Alzheimer's disease Phase II double blind, randomised, placebo-controlled study to assess the efficacy and safety of Xanamem in participants with mild Alzheimer's disease* • 84 patients enrolled (48% of total study cohort) and more than 35 patients already completed study⃰⃰⃰⃰⃰⃰ ⃰
Slide 12: Interim Analysis
Interim Analysis XanADu Interim Analysis Data Safety Monitoring Board (DSMB) analysis to be performed on first 50 evaluable patients DSMB opinion available Q2 2018 DSMB analysis may provide early insights into the XanADu study 12 Xanamem™ - novel approach to Alzheimer Dementia
Slide 13: Investment potential
Investment potential 13 Xanamem™ - novel approach to Alzheimer Dementia
Slide 14: Commercially experienced, globally recognised
Commercially experienced, globally recognised Board of Directors Xanamem Clinical Advisory Board Dr. Geoff Brooke Dr. Bill Ketelbey Dr. Jason Loveridge Dr. George Morstyn Prof. Craig Ritchie Prof. Colin Masters Prof. Jeffrey Cummings Chairman CEO & MD Non-Executive Director Non-Executive Director Ch
Slide 15: Dr Geoff Brooke
Dr Geoff Brooke Dr Geoff Brooke is the Chairman of Actinogen. He graduated in Medicine and Surgery from the University of Melbourne and worked at St Vincent’s Hospital in Melbourne before completing an MBA at IMD in Lausanne in Switzerland. He has spent 30 years in the medical venture capital indust
Slide 16: Peer comparison
Peer comparison 2000 What big pharma companies are paying 1800 for acquisition of drug 1600 developers in the VALUE US$ MILLIONS 1400 X Alzheimer’s space 1200 1000 800 X 600 X 400 200 0 PH I PH II PH III 16 Xanamem™ - novel approach to Alzheimer Dementia
Slide 17: Recent comparable deals
Recent comparable deals Assets with Alzheimer’s disease as the lead indication or key indication Deal Value Upfront Licensee/acquirer Licensor/acquired Year Candidate(s) Phase (US$M) (US$M) Takeda Denali 2018 ATV platform, three programs Pre-clinical ~$1,000 $150 Biogen BMS 2017 BMS-986168 Ph 1 $710
Slide 18: Xanamem™ in closing
Xanamem™ in closing …………. 18 Xanamem™ - novel approach to Alzheimer Dementia
Slide 19: Summary
Summary A huge market with a significant unmet medical need Xanamem XanADu • Differentiated, with a novel mechanism of action • Fully funded to completion • Small molecule - oral • DSMB interim analysis Q2 2018 • High quality development plan and regulatory review • On track for last patient enrolle
Slide 20: Dr. Bill Ketelbey, CEO & Managing Director
Dr. Bill Ketelbey CEO & Managing Director ☏ Main: +61 2 8964 7401 ✉Email: bill.ketelbey@actinogen.com.au www.actinogen.com.au
Slide 21: Appendix
Appendix Actinogen
Slide 22: Xanamem journey of discovery
Xanamem journey of discovery 11β-HSD1 is highly expressed in XanADu First Subject In regions important Carbenoxolone is Xanamem data for cognition shown to enhance published cognitive function Webster et al., Diabetes Cognition Phase II in elderly men and 2017 type II diabetics Xanamem XanADu 11β-HS
Slide 23: Xanamem pipeline of indications, back-up compounds
Xanamem pipeline of indications, back-up compounds* PRE-CLINICAL PHASE I PHASE II Alzheimer’s disease Diabetes Cognitive Impairment & other diseases with possible cortisol induced Cognitive Impairment Post Traumatic Stress Disorder Post Myocardial Infarction * Back-up compounds to Xanamem, licenced
Actinogen Medical — Investor Presentation (March 2018) on 6ix